Drug Targets – Products

Label-free biosensor technologies have emerged as a promising approach to identify high-value hits with a strong likelihood of success as a therapeutic. Unlike traditional approaches of drug discovery, they are fast, sensitive, and come with improved success rates towards high-value drug candidates.

Evergreen Discovery and Orbit Discovery Ltd have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.

Cardiff Oncology, Inc. has announced that the first patient was dosed last month with its investigational drug onvansertib in its Phase II ONSEMBLE trial.

Carterra Inc. launched its latest HT-SPR instrument, the LSAXT, at the Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA.

GenNext Technologies, Inc. has selected Dr. Lisa Jones as the company’s new chief science officer.

Pheno Therapeutics Limited has announced that it has entered into an exclusive worldwide license agreement with UCB.

Energy metabolism plays a central role in a wide variety of cellular and physiological processes. Therefore, a deep understanding of how disruption to energy metabolism impacts cells can help in therapeutic drug discovery and development.

Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.

Ubiquigent Limited today announced the appointment of Dr. Sheelagh Frame, Chief Scientific Officer, to the Company’s Board of Directors.

The MACSima™ Imaging Platform opens the next level of context in spatial biology, allowing fully automated imaging of 100s of protein markers on a single tissue sample. It includes a broad portfolio of pre-validated antibodies and an easy-to-use software generating ready-to-publish images and charts.